Patients with CKD represent a vulnerable population where the risks of atrial fibrillation, ischemic stroke, and bleeding are all heightened. Although large randomized, controlled trials in the general population clearly demonstrate that the benefits of warfarin and direct-acting oral anticoagulants outweigh the risks of bleeding, no such studies have been conducted in patients when their creatinine clearance falls below 25-30 ml/min. Without randomized, controlled trial data, the role of anticoagulation in patients with CKD with atrial fibrillation remains unclear and our practice is informed by a growing body of imperfect literature such as observational and pharmacokinetic studies. This article aims to present a contemporary literature review of the benefits versus harms of anticoagulation in atrial fibrillation for patients with CKD stages 3, 4, 5, and 5 on dialysis. Although unanswered questions and areas of clinical equipoise remain, this piece serves to assist physiciansin interpreting the complex body of literature and applying it to theirclinical care.
Introduction
Stroke is a disabling and sometimes fatal complication of atrial fibrillation (1, 2) . Anticoagulation is recommended to reduce the risk of stroke but also increases the risk of intracranial hemorrhage and other potentially life-threatening bleeding complications. Multiple large randomized, controlled trials (RCTs) in the general population clearly demonstrate that the benefits of warfarin outweigh its risks of severe bleeding (3, 4) . However, this risk/benefit ratio remains less clear for certain subgroups, such as those with CKD states 4, 5, and 5 on dialysis (5[D] ) (5) (6) (7) (8) .
Patients with advanced CKD or dialysis and atrial fibrillation represent a vulnerable population where the risks of atrial fibrillation, stroke, and bleeding are all heightened such that evidence-based guidance on anticoagulation is needed (9, 10) . However, patients with a creatinine clearance ,25-30 ml/min were excluded from almost all pivotal phase 3 trials on anticoagulation such that it remains unclear whether these drugs confer more benefit than harm in advanced CKD (11) (12) (13) (14) . A recent Kidney Disease Quality Outcome Initiative survey confirms this state of equipoise: among 5063 physicians 55% were in favor of anticoagulation in atrial fibrillation for patients with ESKD, whereas the remaining were not (15) . The introduction of direct-acting oral anticoagulants (DOACs) further complicates anticoagulation practices by offering new options in the setting of limited efficacy and safety data in patients with advanced CKD and dialysis.
In this article, we provide a focused review of the clinical literature on oral anticoagulation from the perspective of risk versus benefit in patients with atrial fibrillation with CKD 3, 4, 5, and 5(D) ( Table 1) . Given that anticoagulation in advanced CKD is controversial, we strive to demystify the complex body of literature to provide more clarity on the latest evidence for and against anticoagulation in this population.
Benefits versus Risks of Warfarin in CKD 3, 4, and 5
Warfarin came into medical use in 1954 in an era that preceded Food and Drug Administration (FDA) regulation of rigorous clinical trials in subpopulations such as CKD. Meta-analysis of six RCTs in the general population reported a 62% reduction in all-cause stroke with dose-adjusted warfarin to an achieved international normalized ratio (INR) 2.0-2.6 compared with placebo (number needed to treat532), with a small but significant increased risk for extracranial hemorrhage (number needed to harm5333) (3); however, most of these trials did not enroll patients with CKD. Only Stroke Prevention in Atrial Fibrillation III enrolled 516 patients with stage 3 CKD (eGFR 30-59 ml/min per 1.73 m 2 ) and a post hoc analysis of the RCT reported reduced risk in ischemic stroke and systemic thromboembolism with dose-adjusted warfarin (mean INR52.4) compared with fixed dose warfarin (mean INR51.3) plus aspirin, with no difference in major hemorrhage. These results suggest that warfarin is both effective and safe in CKD 3 ( Table 2) (16) .
In patients with an eGFR,30 ml/min warfarin's effectiveness and safety can only be inferred from observational studies. The results from these observational studies are mixed, which convolutes our understanding of warfarin's risks versus benefits. For instance, an observational Danish national registry cohort of 3587 individuals with atrial fibrillation and CKD 3, 4, and 5 reported a nonsignificant decrease in risk of hospitalization or death from all-cause stroke or systemic thromboembolism with warfarin compared Table 3) . A subsequent study in the same registry of nondialysis patients with atrial fibrillation and CKD (61% CKD 4, 5) attempted to quantify total benefit/harm of warfarin using a "net clinical benefit" outcome. Net clinical benefit was defined as a composite of fatal all-cause stroke and fatal bleeding such that there was more "net benefit" in warfarin users than no treatment in atrial fibrillation (HR, 0.71; 95% CI, 0.57 to 0.88) (18) . Although helpful, the net outcome did not account for morbidity from nonfatal bleeding. Utilization of methods to calculate net benefit of unequally weighted outcomes would yield more relevant outcomes (19) . Another study of 6292 individuals with CKD not on dialysis is notable for distinguishing benefits versus harms by CKD stage. The risk of ischemic stroke and transient ischemic attack while on warfarin compared with no anticoagulation was significantly reduced in CKD 3 but not statistically significant in CKD 4 and 5 (HR, 0.54; 95% CI, 0.26 to 1.13); however, there was no difference in bleeding risk across stages of CKD (20) ( Table 3 ).
In total, there have been at least six well conducted observational studies comparing stroke benefit versus bleeding harm for atrial fibrillation in nondialysis patients with CKD on warfarin in comparison to no anticoagulation. Even among these select studies there is large heterogeneity in results; 67% of these studies reported that warfarin reduced stroke risk and 33% reported no change. Similarly, for bleeding, 67% reported that warfarin increased risk and 33% reported no change ( Table 3 ). As such, the association between warfarin with stroke and bleeding is not reproducible between these studies and the heterogeneity in results may be attributed to bias from observational analyses and variations in study design, which include:
1. Confounding by indication which occurs when patients prescribed warfarin are sicker than patients not prescribed warfarin and sicker patients are at higher risk for stroke and bleeding. 2. Unmeasured confounding which occurs when INR levels are not measured. This makes it impossible to adjust for the degree of anticoagulation if patients are not given therapeutic doses of warfarin. 3. Early drug discontinuation occurring in an intention-totreat analysis will bias results toward the null. 4. Misclassification bias given that stroke and bleeding outcomes were typically ascertained from claims data and not validated against imaging results.
Benefits versus Risks of DOACs in CKD 3, 4, and 5
The introduction of DOACs (dabigatran, apixaban, rivaroxaban, and edoxaban) presents physicians with new options which are equivalent if not superior to warfarin at preventing stroke and major bleeding among patients with atrial fibrillation without kidney impairment (Table 4 ) (11) (12) (13) (14) . When compared with warfarin, DOACs do not require INR monitoring or heparin bridging and are minimally affected by foods containing vitamin K. They may also have fewer drug-drug interactions; however, a recent study highlighted the risk of concurrent use of CYP3A4 and P-glycoprotein modulators which may affect DOAC-related bleeding outcomes (21) . Although not proven, DOACs theoretically pose less risk of arterial calcification compared with warfarin because they do not inhibit the vitamin K-dependent g-carboxylase enzyme (22, 23) . These factors are relevant in CKD where polypharmacy, malnutrition, and coronary artery calcification are highly prevalent. All DOACs are cleared by the kidney which can lead to drug bioaccumulation, supra-therapeutic dosing, and unintended bleeding in patients with kidney impairment (24) (25) (26) . Reversal agents such as idarucizumab and andexanet alfa are approved and are given as intravenous infusions and require less volume than fresh frozen plasma (Table 1 ). However, these medications remain costly, prohibiting their penetration onto hospital formularies. They also carry a risk of thrombotic complications. In the idarucizumab trial, thrombotic events occurred in 5.6% of patients after receiving therapy and included deep-vein thrombosis, pulmonary embolism, left atrial thrombus, myocardial infarction, and ischemic stroke (27) . In the phase 2 trials of andexanet alfa in healthy volunteers, no thromboembolic events were reported (28) . However, an interim analysis of the ongoing phase 3 trial in patients with acute major bleeding reported thrombotic events in 11% and death in 12% of patients within 30 days after administration (29) . The use of these agents requires caution, especially while they are still being tested and their safety is not completely understood.
Unlike Table 4 ). A recent Cochrane review of 12,545 patients with CKD (97% with CKD 3) enrolled in five RCTs reported reduced risk of all-cause stroke and systemic thromboembolism (HR, 0.81; 95% CI, 0.65 to 1.00) and major bleeding (HR, 0.79; 95% CI, 0.59 to 1.04) in comparison with warfarin (33) . Similar findings were also reported in a meta-analysis of DOACs in moderate CKD (34) .
A United States observational study published this July compared outcomes in 3206 DOAC users (dabiatran, rivaroxaban, and apixaban) matched to warfarin users stratified by eGFR (35) . In this study, eGFR did not statistically modify (P-interaction50.70) the risk of ischemic stroke in DOACs when compared with warfarin in participants with eGFR.60 ml/min (HR, 0.94; 95% CI, 0.74 to 1.180) or in participants with eGFR,60 ml/min (HR, 1.02; 95% CI, 0.76 to 1.37). Risk for major and minor bleeding in DOACs was slightly higher when compared with warfarin for eGFR,60 ml/min (HR, 1.23; 95% CI, 1.02 to 1.48) versus eGFR.60 ml/min (HR, 1.01; 95% CI, 0.88 to 1.17) but effect modification was also NS (P-interaction50.10). Subgroup analyses for users with an eGFR,30 ml/min (n5253) showed lower ischemic stroke rates (9.2 versus (35) . Although the sample size was underpowered to detect statistical differences, these findings suggest that systemic DOAC levels increase when kidney disease becomes advanced thereby reducing the risk stroke and increasing the risk of bleeding.
Benefits versus Risks of Warfarin: CKD 5(D)
There are no RCTs of warfarin in patients on dialysis and observational, often retrospective, studies are used to guide practice ( Table 5 ). The results of these observational studies are conflicting. A population-based analysis from Denmark of 901 individuals on dialysis found that warfarin reduced risk of all-cause stroke and systemic thromboembolism by 44% (P50.002) but did not significantly increase the risk of bleeding (HR, 1.27; 95% CI, 0.91 to 1.77) when compared with no therapy (17) . Whereas the risk in bleeding with warfarin is replicated across many studies, the benefit in stroke reduction is less consistent. For example, a United States study of 1671 individuals on dialysis reported a 74% increased risk for all-cause stroke (HR, 1.74; 95% CI, 1.11 to 2.72) among warfarin versus nonwarfarin users (36) . However, other studies report more modest findings, such as a Canadian retrospective population analysis from 1998 to 2007 which reported a nonsignificant increased risk for ischemic stroke (HR, 1.14; 95% CI, 0.78 to 1.67) with warfarin in comparison with no anticoagulation (37) ( Table 5 ). In a meta-analysis of 14 observational studies with 20,398 patients on dialysis, warfarin did not associate with reduced risk of ischemic stroke (HR, 0.77; 95% CI, 0.55 to 1.07) when compared with no warfarin (34) . Within this meta-analysis, a large but nonsignificant increased risk of hemorrhagic stroke (HR, 1.93; 95% CI, 0.93 to 4.00) and a modest but also nonsignificant increased risk of gastrointestinal bleeding (HR, 1.19; 95% CI, 0.8 to 1.76) were reported in warfarin users compared with nonwarfarin users (34) . These observational studies should be interpreted with caution because they are subject to bias from patient selection, intention-to-treat analyses that do not account for early drug discontinuation, time in therapeutic range, and misclassification through nonadjudicated claims for outcomes.
Benefits versus Risks of DOACs: CKD 5(D)
Even though the pivotal RCTs excluded patients with eGFR,25-30 ml/min, DOACs are FDA approved for use down to an eGFR of 15 ml/min on the basis of limited dose pharmacokinetic modeling without clinical safety data (38) (39) (40) (41) . The US FDA label also makes pharmacokinetically based dose recommendations for the use of rivaroxaban (15 mg daily) and apixaban (5 mg twice daily reduced to 2.5 mg twice daily when age.80 years or weight,60 kg) for patients on dialysis; however, the label cautions that these recommendations lack clinical efficacy and safety data validation (39, 40) . As such, we are once again left to rely on observational data to derive effectiveness and safety profiles for DOACs in ESKD.
In late June of this year an observational study of maintenance dialysis Part D Medicare beneficiaries compared 2351 apixaban users to 7053 prognostic score-matched warfarin users (3:1 match) ( Table 5 ). There was no difference in risk of ischemic stroke or systemic embolism (HR, 0.88; 95% CI, 0.69 to 1.12) and a 28% reduced risk of major bleeding (HR, 0.72; 95% CI, 0.59 to 0.87) in the apixiban group compared with warfarin. Ischemic stroke/systemic embolism reduction was greater in the 5 mg twice daily group (HR, 0.61; 95% CI, 0.37 to 0.98) and bleeding risk was not higher (HR, 0.98; 95% CI, 0.68 to 1.42) compared with the 2.5 mg twice daily group (42) .
An earlier study reported significant off-label use of dabigatran and rivaroxaban among 8589 patients on maintenance hemodialysis (43) . Dose reduction for kidney impairment was not seen among 15% of dabigatran users and 32% of rivaroxaban users. In a time-on-treatment analysis, increased risks of hospitalization for bleeding were reported in dabigatran (HR, 2.59; 95% CI, 1.89 to 3.54) and rivaroxaban (HR, 1.90; 95% CI, 1.19 to 3.04) users when compared with warfarin. Fatal bleeding rate ratios were even higher, likely because reversible agents were not available at the time of the study: dabigatran rate ratio, 1.78 (95% CI, 1.18 to 2.68), and rivaroxaban rate ratio, 1.71 (95% CI, 0.94 to 3.12), when compared with warfarin (43) . The risk was attenuated in subgroup analyses of individuals prescribed a reduced dose. The study was underpowered to compare stroke or systemic embolism outcomes due to the infrequency of these events.
Quantification of Stroke and Bleeding Risk in CKD 4, 5, and 5(D)
A key aspect of patient care is quantifying individual risk. In general, stroke risk stratification scores (CHADS 2 , CHA 2 DS 2 -VASc, R 2 CHADS 2 , ATRIA) and bleeding risk scores (HAS-BLED, HEMORR 2 HAGES, ATRIA, and OR-BIT) provide minimal-to-moderate predictive value in the CKD population. In fact, one study found that these scores were no better than physician subjective assessments (44) . CHA 2 DS 2 -VASc, the most widely used stroke risk stratification tool, has been validated in CKD and dialysis; however, it has poor accuracy in discriminating patients who will have a stroke versus those who will not (concordance statistic ,0.6 in CKD stage 3 and ,0.7 in CKD stages 4, 5, and dialysis) (45) . Bleeding risk scores have poor discrimination in the general population (e.g., HEMORR 2 HAGES concordance statistic of 0.66-0.72) and have not been validated in the advanced CKD population.
Recommendations: Benefits versus Risks of Oral Anticoagulation in CKD with Atrial Fibrillation
In patients with CKD 3, our recommendations are consistent with cardiology and nephrology guidelines which advise oral anticoagulation for patients with nonvalvular atrial fibrillation with a CHA 2 DS 2 -VASc score $2 on the basis of extrapolation from general practice (46, 47) . The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines conclude noninferior efficacy in prevention of stroke and systemic thromboembolism and likely superior safety of DOACs compared with warfarin in patients with CKD 3 (47) . Similarly, we recommend the use of a DOAC over warfarin because there are rigorous RCT data suggesting that DOACs are equivalent or superior to warfarin in safety and efficacy when the eGFR is .30 ml/min in concurrence with recent KDIGO statements (47). We also recommend following kidney function at least twice yearly In patients on maintenance HD, warfarin modestly reduced the risk of ischemic stroke.
so that dose adjustments can be made if GFR changes substantially.
In patients with CKD 4, 5, and 5(D), American Heart Association/American College of Cardiology/Heart Rhythm Society (ACC/AHA/HRS) guidelines recommend anticoagulation in patients with a CHA 2 DS 2 -VASc score .2 on the basis of extrapolation from general practice. They support the use of warfarin or reduced doses of DOACs in CKD 4 and 5 even though the safety and efficacy of DOACs have not been established in this group; moreover, ACC/ AHA/HRS do not support dabigatran and rivaroxaban use once patients start dialysis (46) . In contrast, KDIGO statements do not support any routine anticoagulation for stroke prevention in in CKD 4, 5, and 5(D) because there are no RCTs to support use of anticoagulation, in addition to the heighted risk of bleeding in this population, warfarin's association with accelerated vascular calcifications, and likely reduced effectiveness of anticoagulation from competing high mortality rates in CKD 4, 5, and 5(D) (5) . As such, we believe that this represents clinical equipoise: we do not know whether the benefits outweigh the risks of anticoagulation in patients with atrial fibrillation with CKD 4, 5, and 5(D). For DOACs, accumulating evidence suggests a favorable benefit/risk ratio in advanced CKD through pharmacokinetically guided dosing (48) in addition to replicable stroke and bleeding outcomes in moderate CKD subgroup analyses from the original RCT (11) (12) (13) (14) , with similar results in an observational dialysis study (42) ; however, we believe that the totality of evidence is still inadequate to support the safe prescribing of DOACs in CKD 4, 5, and 5(D). If anticoagulation is desired in patients with GFR,30 ml/min, we recommend warfarin and await further evidence from ongoing safety RCTs being conducted in the dialysis population.
Our recommendations differ in the setting of calciphylaxis where prolonged warfarin is associated with developing the disease (49) (50) (51) . Although rare (3.5 new cases per 1000 patient years), calciphylaxis carries a poor prognosis, with 45%-80% 1-year mortality rate (49) . We encourage discontinuing warfarin in patients with calciphylaxis given that the competing risk of mortality is so high, which severely diminishes the stroke prevention benefits of anticoagulation. If anticoagulation is to be used, reduced dose apixaban (2.5 mg twice daily) is appropriate given that pharmacokinetic studies indicated drug bioaccumulation at 5 mg, twice daily dose in ESKD (24-26). Rivaroxaban 15 mg daily may also be reasonable (49) . 
Shared Decision Making
Without robust evidence on anticoagulation in CKD stages 4, 5, and 5(D), we advise a shared decision-making process between the physician and patient on the basis of (1) the patient's values, preferences, and goals; (2) subjective assessment of the individual's baseline risk of stroke and bleeding;
(3) guidance on the benefit in stroke prevention and risk of bleeding with anticoagulation; and (4) understanding of the available options for anticoagulation ( Figure 1 ). Patients benefit from communication with their physicians through health awareness and empowerment (52) . As emphasized in the KDIGO clinical controversies summary, a collaborative team-based approach through communication between primary care, cardiology, and nephrology is important to this complex decision. The American College of Cardiology has created online decision-making tools for clinicians to engage effective conversations with patients about treatment options for anticoagulation (Blood Thinners for AF: A Smart Decision Guide, https://www.cardiosmart.org/SDMAFib).
Future Direction
Two phase 3 RCTs of patients on maintenance dialysis are underway: RENal hemodialysis patients ALlocated apixaban versus warfarin in Atrial Fibrillation (RENAL-AF) (ClinicalTrials Identifier: NCT02942407, n5762) and AXADIA (Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation [AF] and End-Stage Kidney Disease [ESKD]) (ClinicalTrials Identifier: NCT02933697, n5222). These are noninferiority trials with patients randomized to apixaban versus warfarin dose adjusted for INR 2-3. RENAL-AF uses 5 mg twice daily and 2.5 mg twice daily in patients who meet criteria for reduced dose for 15 months. AXADIA uses 2.5 mg twice daily for all patients for 6-24 months. The primary outcome is clinically relevant, nonmajor bleeding. Unfortunately, both of these trials lack a placebo arm and are unlikely to have adequate power to report stroke differences. A third RCT in the dialysis population, Oral Anticoagulation in Haemodialysis Patients (AVKDIAL) (ClinicalTrials Identifier: NCT02886962, n5855), aims to compare the hemorrhagic and thrombotic risks of oral anticoagulation with vitamin K antagonists in comparison with no anticoagulation over 2 years.
Patients with advanced CKD and dialysis represent a vulnerable population at high risk for atrial fibrillation, stroke, and bleeding. Currently, we lack RCTs to answer the fundamental question of whether anticoagulation versus placebo confers more stroke prevention benefit than bleeding risk. Until such rigorous and adequately powered trials are executed, the role of anticoagulation in advanced CKD and dialysis will remain a mystery. Patient wishes not to have anticoagulation -Communicate with family members -Close loop with other providers Patient wishes to have anticoagulation -Communicate with family members -Close loop with other providers Figure 1 . | Anticoagulation is a shared decision between patients and physicians. a Offer to refer the patient to the American College of Cardiology online decision-making tools on stroke and bleeding risks and treatment options for anticoagulation (Blood Thinners for Atrial Fibrillation: A Smart Decision Guide, https://www.cardiosmart.org/SDMAFib).
